COVID-19

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM…

15 hours ago

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responsesOCALA, Fla., Feb. 05, 2026 (GLOBE…

2 days ago

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem…

4 days ago

Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems

This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly…

4 days ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…

5 days ago

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd

UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to…

5 days ago

ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan

For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics,…

5 days ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of…

1 week ago

Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026

2025: strong sales and EPS growth.Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3%…

1 week ago